Literature DB >> 20956519

Exogenous recombinant dimeric neuropilin-1 is sufficient to drive angiogenesis.

Katarzyna A Uniewicz1, Michael J Cross, David G Fernig.   

Abstract

Neuropilin-1 (NRP-1) is present on the cell surface of endothelial cells, or as a soluble truncated variant. Membrane NRP-1 is proposed to enhance angiogenesis by promoting the formation of a signaling complex between vascular endothelial growth factor-A(165) (VEGF-A(165)), VEGF receptor-2 (VEGFR-2) and heparan sulfate, whereas the soluble NRP-1 is thought to act as an antagonist of signaling complex formation. We have analyzed the angiogenic potential of a chimera comprising the entire extracellular NRP-1 region dimerized through an Fc IgG domain and a monomeric truncated NRP-1 variant. Both NRP-1 proteins stimulated tubular morphogenesis and cell migration in HDMECs and HUVECs. Fc rNRP-1 was able to induce VEGFR-2 phosphorylation and expression of the VEGFR-2 specific target, regulator of calcineurin-1 (RCAN1.4). siRNA mediated gene silencing of VEGFR-2 revealed that VEGFR-2 was required for Fc rNRP-1 mediated activation of the intracellular signaling proteins PLC-γ, AKT, and MAPK and tubular morphogenesis. The stimulatory activity was independent of VEGF-A(165). This was evidenced by depleting the cell culture of exogenous VEGF-A(165), and using instead for routine culture VEGF-A(121), which does not interact with NRP-1, and by the inability of VEGF-A sequestering antibodies to inhibit the angiogenic activity of the NRP proteins. Analysis of angiogenesis over a period of 6 days in an in vitro fibroblast/endothelial co-culture model revealed that Fc rNRP-1 could induce endothelial cell tubular morphogenesis. Thus, we conclude that soluble Fc rNRP-1 is a VEGF-A(165)-independent agonist of VEGFR-2 and stimulates angiogenesis in endothelial cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20956519      PMCID: PMC3012965          DOI: 10.1074/jbc.M110.190801

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  72 in total

1.  Comparison of three in vitro human 'angiogenesis' assays with capillaries formed in vivo.

Authors:  D Donovan; N J Brown; E T Bishop; C E Lewis
Journal:  Angiogenesis       Date:  2001       Impact factor: 9.596

Review 2.  Receptor-Fc fusion therapeutics, traps, and MIMETIBODY technology.

Authors:  Chichi Huang
Journal:  Curr Opin Biotechnol       Date:  2009-11-04       Impact factor: 9.740

3.  Exogenous clustered neuropilin 1 enhances vasculogenesis and angiogenesis.

Authors:  Y Yamada; N Takakura; H Yasue; H Ogawa; H Fujisawa; T Suda
Journal:  Blood       Date:  2001-03-15       Impact factor: 22.113

4.  Production of recombinant TRAIL and TRAIL receptor: Fc chimeric proteins.

Authors:  P Schneider
Journal:  Methods Enzymol       Date:  2000       Impact factor: 1.600

5.  Differential expression of neuropilin-1 and neuropilin-2 in arteries and veins.

Authors:  Y Herzog; C Kalcheim; N Kahane; R Reshef; G Neufeld
Journal:  Mech Dev       Date:  2001-11       Impact factor: 1.882

6.  VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding.

Authors:  Shay Soker; Hua-Quan Miao; Masashi Nomi; Seiji Takashima; Michael Klagsbrun
Journal:  J Cell Biochem       Date:  2002       Impact factor: 4.429

7.  Binding and functional comparisons of two types of tumor necrosis factor antagonists.

Authors:  Bernie Scallon; Ann Cai; Nancy Solowski; Amy Rosenberg; Xiao-Yu Song; David Shealy; Carrie Wagner
Journal:  J Pharmacol Exp Ther       Date:  2002-05       Impact factor: 4.030

8.  Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells.

Authors:  Antonio J da Silva; Margot Brickelmaier; Gerard R Majeau; Zhifang Li; Lihe Su; Yen-Ming Hsu; Paula S Hochman
Journal:  J Immunol       Date:  2002-05-01       Impact factor: 5.422

9.  The role of neuropilins in cell signalling.

Authors:  Ian C Zachary; Paul Frankel; Ian M Evans; Caroline Pellet-Many
Journal:  Biochem Soc Trans       Date:  2009-12       Impact factor: 5.407

10.  Response of VEGF expression to amino acid deprivation and inducers of endoplasmic reticulum stress.

Authors:  Steve F Abcouwer; Philip L Marjon; Robyn K Loper; David L Vander Jagt
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-08       Impact factor: 4.799

View more
  10 in total

Review 1.  Neuropilin Functions as an Essential Cell Surface Receptor.

Authors:  Hou-Fu Guo; Craig W Vander Kooi
Journal:  J Biol Chem       Date:  2015-10-08       Impact factor: 5.157

2.  Protein profile of exosomes from trabecular meshwork cells.

Authors:  W D Stamer; E A Hoffman; J M Luther; D L Hachey; K L Schey
Journal:  J Proteomics       Date:  2011-03-08       Impact factor: 4.044

3.  STAT6 Upregulates NRP1 Expression in Endothelial Cells and Promotes Angiogenesis.

Authors:  Peng Gao; Guanghui Ren; Jiangjiu Liang; Ju Liu
Journal:  Front Oncol       Date:  2022-05-05       Impact factor: 5.738

4.  Revascularization of ischemic skeletal muscle by estrogen-related receptor-γ.

Authors:  Antonios Matsakas; Vikas Yadav; Sabina Lorca; Ronald M Evans; Vihang A Narkar
Journal:  Circ Res       Date:  2012-03-13       Impact factor: 17.367

5.  Circulating soluble neuropilin-1 in patients with early cervical cancer and cervical intraepithelial neoplasia can be used as a valuable diagnostic biomarker.

Authors:  Shouhua Yang; Henghui Cheng; Zaiju Huang; Xiaoling Wang; Yinglu Wan; Jing Cai; Zehua Wang
Journal:  Dis Markers       Date:  2015-03-19       Impact factor: 3.434

6.  Characterisation of the interaction of neuropilin-1 with heparin and a heparan sulfate mimetic library of heparin-derived sugars.

Authors:  Katarzyna A Uniewicz; Alessandro Ori; Yassir A Ahmed; Edwin A Yates; David G Fernig
Journal:  PeerJ       Date:  2014-06-26       Impact factor: 2.984

Review 7.  Jack of many trades: Multifaceted role of neuropilins in pancreatic cancer.

Authors:  Pratiek N Matkar; Eric D Jong; Ramya Ariyagunarajah; Gerald J Prud'homme; Krishna K Singh; Howard Leong-Poi
Journal:  Cancer Med       Date:  2018-09-14       Impact factor: 4.452

Review 8.  RCAN1 in cardiovascular diseases: molecular mechanisms and a potential therapeutic target.

Authors:  Shuai Wang; Yuqing Wang; Kaixin Qiu; Jin Zhu; Yili Wu
Journal:  Mol Med       Date:  2020-12-02       Impact factor: 6.354

9.  Vasculogenic mimicry of HT1080 tumour cells in vivo: critical role of HIF-1α-neuropilin-1 axis.

Authors:  Roli M Misra; Manmohan S Bajaj; Vaijayanti P Kale
Journal:  PLoS One       Date:  2012-11-21       Impact factor: 3.240

10.  Differentiation of human pluripotent stem cells to cells similar to cord-blood endothelial colony-forming cells.

Authors:  Nutan Prasain; Man Ryul Lee; Sasidhar Vemula; Jonathan Luke Meador; Momoko Yoshimoto; Michael J Ferkowicz; Alexa Fett; Manav Gupta; Brian M Rapp; Mohammad Reza Saadatzadeh; Michael Ginsberg; Olivier Elemento; Younghee Lee; Sherry L Voytik-Harbin; Hyung Min Chung; Ki Sung Hong; Emma Reid; Christina L O'Neill; Reinhold J Medina; Alan W Stitt; Michael P Murphy; Shahin Rafii; Hal E Broxmeyer; Mervin C Yoder
Journal:  Nat Biotechnol       Date:  2014-10-12       Impact factor: 54.908

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.